WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart).

safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin (HI) in diabetes mellitus in the following categories: (a) in adults ...

an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart. Sanofi-Aventis' Merilog version of the product has been cleared for the treatment of adult and ...

Insulin aspart was the second rapidly acting analogue introduced, approved for clinical use in Europe in 1999 and by the FDA in 2000 for patients with Type 1 or Type 2 diabetes. It is obtained by ...

and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will be reduced by 75%, making it the same ...